Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Set To Finalize Merger With Exopharm, Announces Trading Halt Ahead Of ASX Listing
Tryp Therapeutics Inc. (OTCQB:TRYPF), a Canadian biotech leader in psychedelics, has officially received approval from Exopharm Limited shareholders for their strategic merger, paving the way for a new entity, Tryptamine Therapeutics Limited.
加拿大迷幻藥生物技術領導者Tryp Therapeutics Inc.（OTCQB: TRYPF）的戰略合併已正式獲得Exopharm Limited股東的批准，爲新實體色胺療法有限公司鋪平了道路。
Key Merger Dates And Trading Halt
關鍵合併日期和暫停交易
This approval follows a decisive plan of arrangement initially inked in December last year. The completion is set for May 1, 2024, with trading anticipated to commence on the Australian Securities Exchange (ASX) under the ticker "TYP" by mid-May.
這項批准是在去年12月最初簽署的一項決定性的安排計劃之後獲得的。交易定於2024年5月1日完成，預計將於5月中旬在澳大利亞證券交易所（ASX）開始交易，股票代碼爲 “TYP”。
In preparation for this transition, Tryp will voluntarily halt trading of its shares on the Canadian Securities Exchange and the OTCQB Venture Market starting April 29, 2024. Following the merger, Tryp shares will be delisted as the company transitions fully to the ASX platform.
爲了爲這一過渡做準備，Tryp將從2024年4月29日起自願停止其在加拿大證券交易所和OTCQB風險投資市場的股票交易。合併後，隨着公司完全過渡到澳大利亞證券交易所平台，Tryp的股票將退市。
Merger Details And Shareholder Benefits
合併細節和股東權益
The arrangement, valued at approximately CA$12.8 million ($9.3 million), offers Tryp shareholders a significant premium on their investment, with Exopharm issuing 4.52 ordinary shares for each Tryp share. This merger marks a significant premium based on previous closing prices and aligns with Tryp's strategic vision to enhance shareholder value and expand its clinical programs.
該安排價值約1,280萬加元（合930萬美元），爲Tryp股東提供了可觀的投資溢價，Exopharm爲Tryp每股發行4.52股普通股。根據之前的收盤價，此次合併標誌着可觀的溢價，符合Tryp提高股東價值和擴大其臨床計劃的戰略願景。
Strategic Goals And Expansion Into The Australian Market
戰略目標和向澳大利亞市場的擴張
When the plan of arrangement was announced in December, Tryp's CEO Jason Carroll, highlighted the merger as a milestone that "heralds a new era," aiming to leverage the combined strength of both companies to enhance access to capital and respond dynamically to Australia's evolving psychedelics regulations.
在12月宣佈安排計劃時，Tryp首席執行官傑森·卡羅爾強調此次合併是 “預示着新時代的到來” 的里程碑，旨在利用兩家公司的綜合實力來增加獲得資本的機會，並動態應對澳大利亞不斷變化的迷幻藥監管。
This strategic expansion into the Australian market comes as both companies aim to solidify their footprint in the global biotech landscape, benefiting from Australia's robust platform for biotechnological advancements.
此次對澳大利亞市場的戰略擴張是在兩家公司都希望從澳大利亞強大的生物技術進步平台中鞏固其在全球生物技術領域的足跡之際進行的。
Action Required For Shareholders
股東需要採取的行動
Registered Tryp shareholders are urged to complete the necessary formalities by submitting their shares and the related letter of transmittal to Computershare Investor Services Inc., as outlined in the company's guidance.
敦促註冊的Tryp股東完成必要的手續，如公司指南中所述，向Computershare投資者服務公司提交股票和相關的送文函。
Related News
相關新聞
- Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
- Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
- Psyched：1億美元用於搖頭丸療法、弗吉尼亞州基金、2024年觀察名單、改革更新等
- Tryp Therapeutics在治療腸易激綜合徵和纖維肌痛的新試驗中探索迷幻藥的潛力